A novel therapeutic target, GPR43; where it stands in drug discovery.
With growing interest in human microbiome for its implication in metabolic disorders, inflammatory diseases, immune disorders and so forth, understanding the biology at the interface of the gut flora and the host becomes very important for identifying novel therapeutic avenues. GPR43 has been deorphanized and the metabolites of microbiome, such as short-chain fatty acids, serve as its natural ligands. There are numerous reports that GPR43 might be a crucial link to the novel therapies for the unmet medical needs and many drug discovery organizations are making their moves in response.
Chemical Biology Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongwon, 363-883, Korea.
Sunhong
S
Kim
You-Me
YM
Kim
Young-Shin
YS
Kwak
D050156:Adipogenesis / Q000187:drug effects*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use; D055808:Drug Discovery; D015507:Drugs, Investigational / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008024:Ligands; D008066:Lipolysis / Q000187:drug effects*; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000378:metabolism; D058990:Molecular Targeted Therapy; D050177:Overweight / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015507:Drugs, Investigational; D008024:Ligands; D011956:Receptors, Cell Surface; C473103:FFAR2 protein, human; D043562:Receptors, G-Protein-Coupled